Recent Pfizer Press Releases

  • 6/28/07 3:00 am EDT

    New Phase I Data Evaluating Sunitinib Malate in Patients with Metastatic Colorectal Cancer Presented at the World Congress on Gastrointestinal Cancer

    BARCELONA, Spain--(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard chemotherapy regimen, in patients with metastatic colorectal cancer (mCRC) - cancer originating in the colon that has spread to other parts of the body. In addition, new data from a Phase I study being presented this week at the World Congress on Gastrointestinalmore...
  • 6/25/07 10:06 am EDT
    CHICAGO--(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)more...
  • 6/23/07 11:00 am EDT
    CHICAGO--(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exuberamore...
  • 6/21/07 4:03 pm EDT

    First FDA-Approved Medicine for Fibromyalgia Represents
    Treatment Advance for Millions of Americans Suffering From This Chronic, Widespread Pain Condition

    NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia, one of the most common chronic, widespread pain conditions in the United States. The approval of Lyrica, which received a priority review, represents a breakthrough for the more than six million Americans who suffer from this debilitating condition who previously had no FDAmore...
  • 6/20/07 5:33 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the product labeling as soon as possible. Pfizer is committed to making maraviroc available to the thousands of patientsmore...
  • 6/20/07 1:50 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy. This includes two Phase 3 clinical trials and two Phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical Group (NASDAQ: COLY) in 2005. A scheduled interim analysis of the Phase 3 clinical trials by anmore...
  • 6/12/07 9:09 am EDT

    Pfizer Launches BARC Body Assessment Rating for Canines

    NEW YORK--(BUSINESS WIRE)-- Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first and only FDA-approved veterinary medication for the management of canine obesity, is now available by prescription in the United States. Slentrol was developed in response to the unmet need for a medication to help veterinarians and pet owners better manage canine obesity, an important medical condition that can leadmore...
  • 6/7/07 3:14 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer’s Pratt Business Unit, at the 28th Annual Goldman Sachs Health Care Conference on Thursday, June 14, at 8:40 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on “themore...
  • 6/5/07 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: Compoundmore...
  • 6/4/07 9:05 am EDT

    Phase II Data Examining Efficacy of Axitinib as Single-Agent and in Combination with Chemotherapies Across a Number of Tumor Types Also Presented at ASCO

    CHICAGO--(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, 3) combined with gemcitabine showed a trend towards prolonged overall survival (OS) in patients with advanced pancreatic cancer, compared with gemcitabine alone, according to preliminary data from a randomized Phase II trial. These data were presented at themore...